Core Viewpoint - The company is currently facing legal issues related to the forgery of company seals, but its new drug development projects are progressing as planned, and the management is focused on enhancing operational efficiency and market expansion [1] Group 1: Legal and Operational Updates - The police have preliminarily identified the facts regarding the case of forgery involving He Qinghong, who has been arrested by the Huangyan District Procuratorate, with further investigations ongoing [1] - The company assures that its operations are normal and all business segments are developing steadily [1] Group 2: Strategic Initiatives - The management plans to leverage the innovative policies of the Boao Lecheng Pilot Zone to strengthen external collaborations and increase investment in innovative drug research [1] - The company holds a 51% stake in Boao International Hospital, which is intended to be developed into a high-level clinical research center and translational medicine platform [1] Group 3: Future Focus - In the second half of the year, the management will concentrate on the development of existing business segments, enhance market expansion efforts, and optimize asset utilization to improve operational performance and create greater value for shareholders [1]

(编辑：林辰)关键字： 医药 下半年，公司管理层将进一步聚焦现有业务板块发展，加大市场拓展力度，盘活资产，提升经营业绩水 平，为股东创造更大价值。 （上证路演） 9月25日，济民健康举办2025年半年度业绩说明会。会上管理层回应，截至目前，公安机关已初步查明 "何清红等人伪造公司印章"案的基本事实，何清红已由黄岩区检察院批准逮捕，相关案件仍在进一步侦 查中。目前，公司的新药研发项目均按计划稳步推进中，如果新的进展，公司将依照规则进行披露。目 前公司经营正常，各板块稳健发展，公司管理层将努力提升经营管理水平。 此外，管理层还提到，公司将充分利用海南博鳌乐城先行区的创新政策，进一步加强对外合作，加大对 创新药的研发投入，将博鳌国际医院打造成为高水平的临床研究中心和转化医学平台。 公司目前持有博鳌国际医院51%的股权。其他49%的股份包括公司控股股东双鸽集团及其他自然人，涉 及多方利益。公司后续如有相关安排或进展，公司将及时披露相关信息。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 25 日 （星期四） 10:00-11:00 证券代码：603222 证券简称：济民健康 公告编号：2025-047 济民健康管理股份有限公司 关于召开 2025 年半年度业绩说明会的公告 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 09 月 18 日 （星期四） 至 09 月 24 日 （星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@chimin.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 济民健康管理股份有限公司（以下简称"公司"）已于 2025 年 8 月 21 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果 ...

Core Viewpoint - Jimin Health's stock has shown significant growth this year, with a year-to-date increase of 102.65%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 16, Jimin Health's stock price reached 13.76 CNY per share, with a trading volume of 4.01 billion CNY and a turnover rate of 5.65%, resulting in a total market capitalization of 72.25 billion CNY [1]. - The stock has experienced a 9.64% increase over the last five trading days, a 27.64% increase over the last 20 days, and a 93.53% increase over the last 60 days [1]. - Jimin Health has appeared on the daily trading leaderboard 13 times this year, with the most recent appearance on September 11, where it recorded a net buy of 66.08 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Jimin Health reported a revenue of 366 million CNY, a year-on-year decrease of 21.30%, and a net profit attributable to shareholders of -52.70 million CNY, reflecting a significant decline of 307.10% [2]. - The company's main business revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1]. Group 3: Shareholder Information - As of June 30, Jimin Health had 28,100 shareholders, an increase of 1.40% from the previous period, with an average of 18,703 circulating shares per shareholder, a decrease of 1.38% [2]. - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.74 million CNY distributed over the past three years [3].

Core Viewpoint - The market experienced a slight decline on September 12, with the Shanghai Composite Index down by 0.12%, while the total margin financing balance increased to 23,515.70 billion yuan, up by 111.45 billion yuan from the previous trading day [1] Margin Financing Overview - As of September 12, the margin financing balance in the Shanghai market was 11,954.33 billion yuan, an increase of 74.68 billion yuan; in the Shenzhen market, it was 11,482.71 billion yuan, up by 35.78 billion yuan; and in the Beijing Stock Exchange, it was 78.66 billion yuan, an increase of 1.00 billion yuan [1] - The total margin financing balance across Shanghai, Shenzhen, and Beijing markets reached 23,515.70 billion yuan, reflecting a total increase of 111.45 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 21 sectors saw an increase in margin financing, with the electronics sector leading, gaining 4.645 billion yuan; followed by non-ferrous metals and banking, which increased by 2.983 billion yuan and 1.425 billion yuan, respectively [1] Individual Stock Performance - A total of 1,794 stocks experienced an increase in margin financing, accounting for 48.20% of the total, with 354 stocks seeing an increase of over 5% [1] - The stock with the highest increase in margin financing was Taihu Yuanda, with a latest margin financing balance of 8.5912 million yuan, reflecting an increase of 87.79%, despite a price drop of 1.08% on the same day [1] - Other notable stocks with significant increases in margin financing included Shunyu Precision and Chipone, with increases of 82.52% and 79.44%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the highest increase in margin financing, the average price increase was 4.35%, with Chipone, World, and Saiwei Microelectronics leading with gains of 20.00%, 15.36%, and 11.00%, respectively [2] - Conversely, the stocks with the largest declines included Jimin Health, Chuangyuan Xinke, and Shuguang Digital Innovation, with declines of 5.90%, 5.29%, and 4.06%, respectively [2] Margin Financing Declines - In contrast to the stocks with increased margin financing, 1,927 stocks saw a decrease, with 276 stocks experiencing a decline of over 5% [4] - The stock with the largest decrease in margin financing was Chicheng Co., with a latest balance of 2.8533 million yuan, down by 63.63% from the previous trading day [5] - Other stocks with significant declines included Zhongke Meiling and Zhonghuan Co., with decreases of 46.05% and 29.60%, respectively [4][5]

Core Viewpoint - Jimin Health (603222) experienced a significant increase in stock price, reaching the daily limit, with a turnover rate of 16.96% and a transaction volume of 1.202 billion yuan, indicating strong market interest and trading activity [1][2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's daily trading report due to a price fluctuation of 18.35%, with a net buying amount of 66.0795 million yuan from brokerage seats [1]. - The top five brokerage seats accounted for a total transaction volume of 289 million yuan, with a buying amount of 178 million yuan and a selling amount of 111 million yuan, resulting in a net buying of 66.0795 million yuan [1][2]. - The largest buying brokerage was Huafu Securities, with a purchase amount of 59.0385 million yuan, while the largest selling brokerage was CITIC Securities, with a selling amount of 46.6849 million yuan [3]. Fund Flow - The stock saw a net inflow of 237 million yuan from major funds today, with a significant inflow of 263 million yuan from large orders, while smaller orders saw a net outflow of 25.9314 million yuan [2]. - Over the past five days, the stock has experienced a total net inflow of 290 million yuan [2]. Margin Trading Data - As of September 10, the margin trading balance for the stock was 197 million yuan, with a financing balance of 197 million yuan and a securities lending balance of 115,000 yuan [2]. - In the last five days, the financing balance increased by 224,900 yuan, reflecting a growth rate of 0.11%, while the securities lending balance increased by 22,900 yuan, with a growth rate of 24.84% [2]. Financial Performance - According to the semi-annual report released on August 21, the company achieved a revenue of 366 million yuan in the first half of the year, representing a year-on-year decline of 21.30%, and reported a net loss of 52.6959 million yuan [2].

Group 1 - The core point of the article highlights the significant stock price movements of Jimin Health, with a closing price increase of 33.78% from September 8 to September 11, 2025 [1] - The stock experienced a trading limit increase on September 11, with a turnover rate of 16.96%, indicating high trading activity [1] - Over the past 30 trading days, the stock's price deviation from the Shanghai A-share index reached 94.72%, suggesting substantial volatility in its trading performance [1] Group 2 - The company has shown a pattern of large price fluctuations, with multiple trading days experiencing rapid increases and decreases [1] - There is a warning regarding the potential for a quick decline in stock price due to the observed trading anomalies [1]

Key Points - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets on September 11, 2025 [3] Group 1: Major Events - Taihe Intelligent announced that Sunshine New Energy will acquire 5.79% of its shares from shareholder Xu Dahong at a price of 22.35 yuan per share, totaling 237 million yuan [4] - Chengdi Xiangjiang received a warning letter from the Shanghai Securities Regulatory Commission due to inaccuracies in financial data disclosure in its annual and quarterly reports [5][6] - Sike Rui terminated its capital increase agreement with Changying Hengrong due to external factors, which will not impact its financial status [7] - Jinko Technology plans to invest 30 million USD in an overseas private equity fund to explore applications of new technologies [8] - Western Gold's subsidiary will undergo equipment maintenance until the end of the year, affecting its production capacity [9] Group 2: Share Transfers - Daye Intelligent's actual controller plans to transfer 8% of the company's shares to a private equity fund at a price of 6.75 yuan per share, totaling 171 million yuan [10] - Jimin Health's stock has seen significant fluctuations, with a recent increase of 33.78% over a few days, raising concerns about potential rapid declines [14] Group 3: Acquisitions and Investments - Yangjie Technology intends to acquire 100% of Better Electronics for 2.218 billion yuan, which will become a wholly-owned subsidiary [15] - *ST Jinke's stock will resume trading on September 12, 2025, following a capital increase plan [16] Group 4: Contracts and Projects - Haixia Environmental plans to sign a contract for a photovoltaic microgrid energy management project with its controlling shareholder, with expected transactions not exceeding 21 million yuan [18] - Jilin Expressway's subsidiary won a construction project worth 9.592 billion yuan [19] - *ST Songfa's subsidiary signed contracts for the construction of four container ships, with a total value between 300 million and 500 million USD [20] Group 5: Shareholder Actions - Baicheng Pharmaceutical's controlling shareholder raised the share buyback price to no more than 80 yuan per share [21] - Mountain Outside Mountain's shareholders plan to reduce their holdings by up to 4.08% [22] - Jinpu Garden's shareholders plan to reduce their holdings by up to 4.58% [24] - Suqian Liansheng's shareholder plans to reduce their holdings by up to 3% [25] Group 6: Financing and Debt - CITIC Securities received approval to publicly issue bonds totaling up to 60 billion yuan [34]

Group 1 - China Shipbuilding has completed the share swap absorption merger with China Shipbuilding Industry Corporation, with 3.053 billion new shares listed on September 16, 2025 [1] - Transsion Holdings' shareholder plans to transfer 2% of the company's shares, amounting to approximately 22.807 million shares [1] Group 2 - Chipone Technology reported a record high in new orders from July 1 to September 11, 2025, totaling 1.205 billion yuan, with AI computing orders accounting for about 64% [2] - Chipone Technology's total order amount reached 3.025 billion yuan by the end of the second quarter of 2025, indicating a significant increase [2] Group 3 - Chipone Technology plans to acquire 97.0070% equity of Chipai Technology through a combination of share issuance and cash payment, with the stock resuming trading on September 12 [3] Group 4 - Xinjun Network received a notice of share reduction from its major shareholder, Shanghai Senxiao Investment Center, which reduced its holdings by 1.6271 million shares, bringing its ownership down to 5.29% [4] Group 5 - Yangjie Technology intends to acquire 100% equity of Better Electronics for 2.218 billion yuan, with a profit commitment of no less than 555 million yuan from 2025 to 2027 [5] Group 6 - Shoukai Co. announced that its subsidiary, Yingxin Company, indirectly holds approximately 0.3% equity in Yushu Technology, indicating a low ownership stake [6] Group 7 - Xiamen Airport reported a total passenger throughput of 2.707 million in August, representing a year-on-year increase of 5.18% [9] - *ST Tianshan experienced a significant decline in livestock sales revenue, down 95.80% year-on-year in August [9] Group 8 - Taihe Intelligent's shareholder plans to transfer 5.79% of the company's shares to Sunshine New Energy [9] - Jilin Expressway's subsidiary won a construction project worth 9.592 billion yuan [9] - Tianyong Intelligent secured a project with SAIC Group for engine assembly line renovation [9]

Core Viewpoint - Jimin Health (603222.SH) has issued a risk warning due to significant stock price fluctuations and a notable divergence from its operational performance, indicating potential risks for investors [1] Stock Performance - The company's stock closed at a daily limit increase, with a turnover rate of 16.96% - From September 8 to 11, 2025, the cumulative increase in closing price reached 33.78% - Over the past 30 trading days, the stock's price deviation from the Shanghai A-share index has accumulated to 94.72% [1] Financial Performance - For the fiscal year 2024, the net profit attributable to the parent company was -59.71 million yuan - In the first half of 2025, the net profit attributable to the parent company was -52.70 million yuan - The company is currently in a loss position, and its stock price trend is significantly deviating from its operational performance [1]